Depression has emerged as a ‘silent killer’ in several regions across the world, particularly in urban cities. The prevalence of depression continues to grow rapidly with considerably high mortality and morbidity rate due to which, the healthcare sector continues its pursuit of novel medications and therapies. Antidepressants are prescribed in serious to mild mental health conditions such as major depression and anxiety. Antidepressant drug category is highly lucrative due to low availability of alternative drug therapies for the treatment of such disorders. Drug manufacturers are increasingly advancing the antidepressant drug category by introducing innovative therapies such as selective serotonin reuptake inhibitors (SSRIs) and selective norepinephrine reuptake inhibitors (SNRIs). Depression is one of the most common mental disorders, which are primarily treated by antidepressants. According to National Health Service Digital (NHS Digital), UK, antidepressant medication prescription observed the largest increase in 2016.
Market Dynamics
The global depression drugs market is driven by factors such as absence of alternative therapies and high presence of generic drug manufacturers in the market. Increasing number of major drugs are losing patent protection due to which increasing number of generic manufacturers are developing product variations, which in turn is boosting the growth of the market. Proven effectiveness of these medications in improving medical outcomes and increasing prevalence of disorders such as depression are fueling growth of the market.
For instance, Fetzima, manufactured by Allergan Plc., is protected by three patents, which are expected to expire in 2031, 2032, and 2023.
However, life threatening side effects associated with these medications as indicated by the black box warning on the packaging, as well as lack of research and development by major players are expected to hinder growth of the depression drugs market.
Key features of the study:
- This report provides an in-depth analysis of the global depression drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global depression drugs market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Merck & Co., Inc., GlaxoSmithKline plc, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Johnson & Johnson, Sanofi S.A., Pfizer, Inc., Allergan plc, H. Lundbeck A/S, and Alkermes
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global depression drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global depression drugs market
- Global Depression Drugs Market, By Drug Type:
- Antidepressants
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Serotonin Norepinephrine Reuptake Inhibitor (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Others (CNS Stimulants, Monoamine Oxidase Inhibitors)
- Global Depression Drugs Market, By Indication:
- Major Depressive Disorder (MDD)
- Bipolar Disorder
- Dysthymic Disorder
- Postpartum Depression
- Seasonal Affective Disorder (SAD)
- Premenstrual Dysphoric Disorder (PMDD)
- Others
- Global Depression Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Depression Drugs Market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- Merck & Co., Inc.
- GlaxoSmithKline plc
- AstraZeneca Plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Johnson & Johnson
- Sanofi S.A.
- Pfizer, Inc.
- Allergan plc
- Lundbeck A/S
- Alkermes
- 1. Research Objective and Assumption
- Research Objectives
- Assumptions
- Abbreviations
- 2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Type
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- 3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Drug Launches
- Epidemiology
- Pipeline Analysis
- Distribution Landscape
- Merger, Acquisition, and Collaborations
- Regulatory Scenario
- Key Developments
- PEST Analysis
- 4. Global Depression Therapeutics Market – COVID-19 Impact Analysis
- Economic Impact
- COVID-19 Epidemiology
- Impact on Supply and Demand
- 5. Global Depression Therapeutics Market, By Drug Type, 2020 – 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Antidepressants
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Selective Norepinephrine Reuptake Inhibitors (SNRIs)
- Serotonin Modulators
- Tricyclic & Tetracyclic Antidepressants
- Atypical Antidepressants
- Antipsychotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- 6. Global Depression Therapeutics Market, By Indication, 2020 – 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Major Depressive Disorder (MDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Bipolar Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Dysthymic Disorder
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Postpartum Depression
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Seasonal Affective Disorder (SAD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Premenstrual Dysphoric Disorder (PMDD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Segment Trends
- 7. Global Depression Therapeutics Market, By Distribution Channel, 2020 – 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2032, (US$ Bn)
- 8. Global Depression Therapeutics Market, By Region, 2020 – 2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021–2032
- Segment Trends
- North America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2020 –2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2020 –2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2020–2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 –2032, (US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2020 –2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2020 –2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2020–2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 –2032, (US$ Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2020 –2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2020 –2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2020–2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 –2032, (US$ Bn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2020 –2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2020 –2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2020–2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 –2032, (US$ Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2020 –2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2020 –2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2020–2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2020 –2032, (US$ Bn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast,Y-o-Y Growth and By Drug Type, 2020 –2032, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Indication, 2020 –2032, (US$ Bn)
- Market Size and Forecast,Y-o-Y Growth and By Distribution Channel, 2020–2032, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country/ Region, 2020 –2032, (US$ Bn)
- North Africa
- Central Africa
- South Africa
- 9. Competitive Landscape
- Company Profiles
- Johnson & Johnson*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Overview
- Strategies
- GlaxoSmithKline plc.
- Otsuka Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Company Limited.
- Eli Lilly and Company
- Sanofi S.A.
- Pfizer, Inc.
- Allergan plc.
- H. Lundbeck A/S
- Alkermes
- Allergan
- Novartis AG
- Biogen
- Sage Therapeutics, Inc.
- AbbVie Inc.
- 10. Section
- References
- Research Methodology
- About us and Sales Contact
- *Browse 36 market data tables and 26 figures on “Global Depression Therapeutics Market” – Global forecast to 2032
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook